0001628280-21-014943.txt : 20210730 0001628280-21-014943.hdr.sgml : 20210730 20210729185242 ACCESSION NUMBER: 0001628280-21-014943 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210728 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events FILED AS OF DATE: 20210730 DATE AS OF CHANGE: 20210729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARDELYX, INC. CENTRAL INDEX KEY: 0001437402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36485 FILM NUMBER: 211129199 BUSINESS ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 510-745-7047 MAIL ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: NTERYX INC DATE OF NAME CHANGE: 20080611 8-K 1 ardx-20210728.htm 8-K ardx-20210728
0001437402false00014374022021-07-282021-07-280001437402dei:OtherAddressMember2021-07-282021-07-28


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2021
ardx-20210728_g1.jpg
ARDELYX, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3648526-1303944
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
34175 ARDENWOOD BLVD.FREMONTCALIFORNIA 94555
400 FIFTH AVE.SUITE 210WALTHAMMASSACHUSETTS 02451
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (510745-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001ARDXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 1.01 Entry into a Material Definitive Agreement.

On July 29, 2021, Ardelyx, Inc. (the “Company”) entered into that certain Fourth Amendment to Loan and Security Agreement (the “Amendment”), which amended that certain Loan and Security Agreement, dated as of May 16, 2018 (as amended, restated or modified from time to time, including by that certain First Amendment to Loan and Security Agreement, dated as of October 9, 2020, that certain Second Amendment to Loan and Security Agreement, dated as of March 1, 2021, and that certain Third Amendment to Loan and Security Agreement, dated as of May 5, 2021, the “Loan and Security Agreement”) among the Company, Solar Capital Ltd. and the lenders party thereto, by extending the period of time that the Company is permitted to make interest-only payments on the term loan facility under the Loan Agreement to November 1, 2021. Without such extension, following the July 28, 2021 issuance by the U.S. Food and Drug Administration (“FDA”) of a complete response letter (“CRL”) for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (“CKD”) on dialysis, the interest only period had been set at August 1, 2021.

The above summaries of the material terms of the Amendment do not purport to be complete and are qualified in their entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1, respectively, to this Current Report on Form 8-K and incorporated by reference herein.

Item 8.01 Other Events.

On July 29, 2021, the Company announced that it received a complete response letter (“CRL”) from the U.S. Food and Drug Administration (the “FDA”) on July 28, 2021 regarding the Company’s New Drug Application (“NDA”) for the control of serum phosphorus in chronic kidney disease (“CKD”) patients on dialysis. According to the CRL, while the FDA agrees “that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis,” the Agency characterizes the magnitude of the treatment effect as “small and of unclear clinical significance.” Additionally, the FDA noted that for the application to be approved, Ardelyx will need “to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in CKD patients on dialysis.” There were no safety, clinical pharmacology/biopharmaceutics, chemistry, manufacturing, and controls or non-clinical issues identified in the CRL.

The Company intends to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 29, 2021ARDELYX, INC.
By:/s/ Elizabeth Grammer
Elizabeth Grammer
Chief Legal and Administrative Officer

EX-10.1 2 fourthamendmenttoloanandse.htm EX-10.1 Document

FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this
Amendment”), dated as of July 29, 2021 (the “Amendment Effective Date”), is made by and among Ardelyx, Inc., a Delaware corporation (“Borrower”), SLR Investment Corp., a Maryland corporation and formerly known as Solar Capital Ltd. (“Solar”), in its capacity as collateral agent for Lenders (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and the Lenders listed on Schedule 1.1 of the Loan and Security Agreement (as defined below) or otherwise a party hereto from time to time including Solar in its capacity as a Lender and Western Alliance Bank, an Arizona corporation, as a Lender (each a “Lender” and collectively, the “Lenders”).

The Borrower, the Lenders and Collateral Agent are parties to a Loan and Security Agreement dated as of May 16, 2018 (as amended, restated or modified from time to time, including by that certain First Amendment to Loan and Security Agreement, dated as of October 9, 2020, that certain Second Amendment to Loan and Security Agreement, dated as of March 1, 2021, and that certain Third Amendment to Loan and Security Agreement, dated as of May 5, 2021, the “Loan and Security Agreement”). The Borrower has requested that the Lenders agree to certain amendments to the Loan and Security Agreement. The Lenders have agreed to such request, subject to the terms and conditions hereof.

Accordingly, the parties hereto agree as follows:

SECTION 1 Definitions; Interpretation.

(a)Terms Defined in Loan and Security Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan and Security Agreement.

(b)Interpretation. The rules of interpretation set forth in Section 1.1 of the Loan and Security Agreement shall be applicable to this Amendment and are incorporated herein by this reference.

SECTION 2 Amendments to the Loan and Security Agreement.

(a)The Loan and Security Agreement shall be amended as follows effective as of the Amendment Effective Date:

(i)Section 2.2(b)(ii) of the Loan and Security Agreement is amended and restated as
follows:

“(ii) Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall (i) make monthly payments of interest to the respective Lender to which such payments are owed in accordance with their respective Pro Rata Shares, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon the effective rate of interest applicable to the Term Loan, as determined in Section 2.3(a) plus (ii) make consecutive equal monthly payments of principal to the respective Lender to which



such payments are owed in accordance with their respective Pro Rata Shares, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (A) the respective principal amounts of such Lender’s Term Loan outstanding less the additional principal payment (if any) pursuant to the proviso at the end of this sentence, and (B) a repayment schedule equal to the number of months from (and including) the Amortization Date through (and including) the Maturity Date; provided, however, if the Amortization date is November 1, 2021, Borrower shall make an additional principal payment to Lenders on such date in an amount equal to $13,888,888.89, without any Prepayment Premium in respect of such additional principal payment. All unpaid principal and accrued and unpaid interest with respect to each such Term Loan is due and payable in full on the Maturity Date. The Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).”

(ii)The defined term “Amortization Date” is hereby amended and restated in its entirety as follows:

Amortization Date” means December 1, 2021; provided, however, if the FDA does not approve the Borrower’s New Drug Application for tenapanor for control of serum phosphorus in adult chronic kidney disease patients (CKD) on dialysis on or before October 25, 2021, subject to reasonable verification by Collateral Agent (including supporting documentation reasonably requested by Collateral Agent), then the Amortization Date shall mean November 1, 2021.

(b)References Within Loan and Security Agreement. Each reference in the Loan and Security Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment.

SECTION 3    Conditions of Effectiveness. The effectiveness of Section 2 of this Amendment shall be subject to the satisfaction of each of the following conditions precedent:

(a)Fees and Expenses. The Borrower shall have paid (i) an amendment fee of Fifty Thousand Dollars ($50,000) to be shared between the Lenders seventy percent (70%) to Solar and thirty percent (30%) to Western Alliance Bank, and (ii) all invoiced costs and expenses then due in accordance with Section 5(e).

(b)This Amendment. Collateral Agent shall have received this Amendment, executed by Collateral Agent, the Lenders and the Borrower.

(c)Representations and Warranties; No Default. On the Amendment Effective Date, after giving effect to the amendment of the Loan and Security Agreement contemplated hereby:

(i)The representations and warranties contained in Section 4 shall be true and correct in all material respects on and as of the Amendment Effective Date as though made on and as of such date; and

(ii)There exist no Events of Default.

SECTION 4 Representations and Warranties. To induce the Lenders to enter into this Amendment, the Borrower hereby confirms, as of the date hereof, (a) that the representations and warranties made by



it in Section 5 of the Loan and Security Agreement and in the other Loan Documents are true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; (b) that there has not been and there does not exist a Material Adverse Change; and (c) that the information included in the Perfection Certificate most recently delivered to Collateral Agent pursuant to Section 6.2(a)(xiv) of the Loan Agreement remains true and correct in all material respects. For the purposes of this Section 4, (i) each reference in Section 5 of the Loan and Security Agreement to “this Agreement,” and the words “hereof,” “herein,” “hereunder,” or words of like import in such Section, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment, and (ii) any representations and warranties which relate solely to an earlier date shall not be deemed confirmed and restated as of the date hereof (provided that such representations and warranties shall be true, correct and complete in all material respects as of such earlier date).

SECTION 5 Miscellaneous.

(a)Loan Documents Otherwise Not Affected; Reaffirmation. Except as expressly amended pursuant hereto or referenced herein, the Loan and Security Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects. The Lenders’ and Collateral Agent’s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future. The Borrower hereby reaffirms the grant of security under Section 4.1 of the Loan and Security Agreement and hereby reaffirms that such grant of security in the Collateral secures all Obligations under the Loan and Security Agreement, including without limitation any Term Loans funded on or after the Amendment Effective Date, as of the date hereof.

(b)Conditions. For purposes of determining compliance with the conditions specified in Section 3, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless Collateral Agent shall have received notice from such Lender prior to the Amendment Effective Date specifying its objection thereto.

(c)Release. In consideration of the agreements of Collateral Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Collateral Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Collateral Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or in relation to, or in any way in connection with the Loan Agreement,



or any of the other Loan Documents or transactions thereunder or related thereto. Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.

(d)No Reliance. The Borrower hereby acknowledges and confirms to Collateral Agent and the Lenders that the Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person. Costs and Expenses. The Borrower agrees to pay to Collateral Agent within the later of (i) ten (10) days following its receipt of an invoice, or (ii) ten (10) days following the Amendment Effective Date, the reasonable and documented out-of-pocket costs and expenses of Collateral Agent and the Lenders party hereto, and the reasonable and documented fees of counsel to Collateral Agent and the Lenders party thereto, in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the Amendment Effective Date.

(e)Binding Effect. This Amendment binds and is for the benefit of the successors and permitted assigns of each party.

(f)Governing Law. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAWS OTHER THAN THE LAWS OF THE STATE OF NEW YORK (OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW)), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, REGARDLESS OF THE LOCATION OF THE COLLATERAL.

(g)Complete Agreement; Amendments; Exit Fee Agreement. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents. For the avoidance of doubt and notwithstanding anything to the contrary in this Amendment, Borrower (a) reaffirms its obligations under the Exit Fee Agreement, including without limitation its obligation to pay the Exit Fee (as defined in the Exit Fee Agreement) if and when due thereunder, and (b) agrees that the defined term “Loan Agreement” as defined in the Exit Fee Agreement shall on and after the Amendment Effective Date mean the Loan and Security Agreement as amended by this Amendment and may be amended, restated or modified from time to time on or after the Amendment Effective Date.

(h)Severability of Provisions. Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.

(i)Counterparts. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original,



and all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

(j)Loan Documents. This Amendment and the documents related thereto shall constitute Loan Documents

(k)Electronic Execution of Certain Other Documents. The words “execution,” “execute”, “signed,” “signature,” and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[Balance of Page Intentionally Left Blank; Signature Pages Follow]




IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.
BORROWER:

ARDELYX, INC.,
as Borrower


By: /s/ Justin Renz
Name: Justin Renz
Title: Chief Financial Officer

COLLATERAL AGENT AND LENDER: SLR INVESTMENT CORP.,
as Collateral Agent and a Lender


By: /s/ Anthony Storino
Name: Anthony Storino
Title: Authorized Signatory


LENDER:

SCP PRIVATE CREDIT INCOME FUND SPV, LLC,
as a Lender


By: /s/ Anthony Storino
Name: Anthony Storino
Title: Authorized Signatory

LENDER:

WESTERN ALLIANCE BANK,
as a Lender


By: /s/ Bill Wickline
Name: Bill Wickline
Title: Head of Life Sciences


EX-101.SCH 3 ardx-20210728.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 ardx-20210728_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 ardx-20210728_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, State or Province Entity Address, State or Province Cover Entity Addresses [Line Items] Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Entity Emerging Growth Company Entity Emerging Growth Company Soliciting Material Soliciting Material Address Type [Domain] Address Type [Domain] City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Cover [Abstract] Entity Addresses [Table] Entity Addresses [Table] Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Co-Headquarter Other Address [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Document Type Document Type Entity Registrant Name Entity Registrant Name Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 6 ardx-20210728_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 ardx-20210728_g1.jpg begin 644 ardx-20210728_g1.jpg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end XML 8 ardx-20210728_htm.xml IDEA: XBRL DOCUMENT 0001437402 2021-07-28 2021-07-28 0001437402 dei:OtherAddressMember 2021-07-28 2021-07-28 0001437402 false 8-K 2021-07-28 ARDELYX, INC. DE 001-36485 26-1303944 34175 ARDENWOOD BLVD. FREMONT CA 94555 400 FIFTH AVE. SUITE 210 WALTHAM MA 02451 510 745-1700 false false false false Common Stock, par value $0.0001 ARDX NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Jul. 28, 2021
Cover  
Document Type 8-K
Document Period End Date Jul. 28, 2021
Entity Registrant Name ARDELYX, INC.
Entity Central Index Key 0001437402
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-36485
Entity Tax Identification Number 26-1303944
Entity Address, Address Line One 34175 ARDENWOOD BLVD.
Entity Address, City or Town FREMONT
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94555
City Area Code 510
Local Phone Number 745-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol ARDX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Co-Headquarter  
Cover  
Entity Address, Address Line One 400 FIFTH AVE.
Entity Address, Address Line Two SUITE 210
Entity Address, City or Town WALTHAM
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 2 96 1 false 1 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.ardelyx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ardx-20210728.htm ardx-20210728.xsd ardx-20210728_def.xml ardx-20210728_lab.xml ardx-20210728_pre.xml fourthamendmenttoloanandse.htm ardx-20210728_g1.jpg http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ardx-20210728.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 2, "dts": { "definitionLink": { "local": [ "ardx-20210728_def.xml" ] }, "inline": { "local": [ "ardx-20210728.htm" ] }, "labelLink": { "local": [ "ardx-20210728_lab.xml" ] }, "presentationLink": { "local": [ "ardx-20210728_pre.xml" ] }, "schema": { "local": [ "ardx-20210728.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 1, "nsprefix": "ardx", "nsuri": "http://www.ardelyx.com/20210728", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ardx-20210728.htm", "contextRef": "id3ff6c78c9594d9c9fd9e79838313770_D20210728-20210728", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.ardelyx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ardx-20210728.htm", "contextRef": "id3ff6c78c9594d9c9fd9e79838313770_D20210728-20210728", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]", "terseLabel": "Cover" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]", "terseLabel": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_OtherAddressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other address for entity", "label": "Other Address [Member]", "terseLabel": "Co-Headquarter" } } }, "localname": "OtherAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ardelyx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001628280-21-014943-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-014943-xbrl.zip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